Form Bio says now is the time to launch - despite cooling software sales
As companies aim to cut costs and cut spending amid uncertain macro conditions, Form Bio believes now is actually the perfect time to launch its platform. The software company was developed by Colossal Biosciences, known for its goal of reviving extinct creatures like the woolly mammoth, and is now launching on its own.
The Form Bio software developed is intended to bring a suite of workflow solutions to the computational biology space, which uses data and modeling to understand biological systems and includes sectors such as gene therapy and biotechnology.
The platform will use machine learning to help researchers and companies move from idea to scientific breakthrough faster by simplifying the processes of analyzing intermediate data and allowing users to choose from existing workflow templates that can be modified to meet a company's specific needs.< /p>
Form Bio announced it was separating from Colossal Biosciences on September 27 with $30 million in funding led by Colossal Biosciences investors JAZZ Venture Partners and Thomas Tull.
Kent Wakeford, the co-CEO of Form Bio and Colossal, said the idea for Form Bio started on day one of Colossal's journey when they tried to get started and realized it wouldn't work. there was no single software they could use.
As companies aim to cut costs and cut spending amid uncertain macro conditions, Form Bio believes now is actually the perfect time to launch its platform. The software company was developed by Colossal Biosciences, known for its goal of reviving extinct creatures like the woolly mammoth, and is now launching on its own.
The Form Bio software developed is intended to bring a suite of workflow solutions to the computational biology space, which uses data and modeling to understand biological systems and includes sectors such as gene therapy and biotechnology.
The platform will use machine learning to help researchers and companies move from idea to scientific breakthrough faster by simplifying the processes of analyzing intermediate data and allowing users to choose from existing workflow templates that can be modified to meet a company's specific needs.< /p>
Form Bio announced it was separating from Colossal Biosciences on September 27 with $30 million in funding led by Colossal Biosciences investors JAZZ Venture Partners and Thomas Tull.
Kent Wakeford, the co-CEO of Form Bio and Colossal, said the idea for Form Bio started on day one of Colossal's journey when they tried to get started and realized it wouldn't work. there was no single software they could use.
What's Your Reaction?
